Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44,514 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96.
Su B, Gao G, Wang M, Lu Y, Li L, Chen C, Chen Y, Song C, Yu F, Li Y, Liu Y, Luo Y, He H, Cheng C, Xu L, Zhang T, Sun L, Liu A, Xia W, Qin Y, Zhao Q, Wei H, Cai W, Chen Y, Zhang F, Wu H. Su B, et al. Among authors: lu y. Lancet Reg Health West Pac. 2023 Apr 24;36:100769. doi: 10.1016/j.lanwpc.2023.100769. eCollection 2023 Jul. Lancet Reg Health West Pac. 2023. PMID: 37547039 Free PMC article.
Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Tao X, Lu Y, Zhou Y, Zhang L, Chen Y. Tao X, et al. Among authors: lu y. Int J Infect Dis. 2020 Apr;93:108-117. doi: 10.1016/j.ijid.2020.01.035. Epub 2020 Jan 25. Int J Infect Dis. 2020. PMID: 31988012 Free article. Review.
A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections: Study protocol for antiretroviral therapy timing in AIDS patients with toxoplasma encephalitis.
Zeng YM, Li Y, He XQ, Huang YQ, Liu M, Yuan J, Bai Y, Lu YQ, Li H, Chen YK. Zeng YM, et al. Among authors: lu yq. Medicine (Baltimore). 2020 Jul 17;99(29):e21141. doi: 10.1097/MD.0000000000021141. Medicine (Baltimore). 2020. PMID: 32702867 Free PMC article. Clinical Trial.
No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
Huang YQ, Tang SQ, Xu XL, Zeng YM, He XQ, Li Y, Harypursat V, Lu YQ, Wan Y, Zhang L, Sun QZ, Sun NN, Wang GX, Yang ZP, Chen YK. Huang YQ, et al. Among authors: lu yq. Front Pharmacol. 2020 Jul 14;11:1071. doi: 10.3389/fphar.2020.01071. eCollection 2020. Front Pharmacol. 2020. PMID: 32765274 Free PMC article.
A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections: Study protocol for the optimal early intervention for cryptococcal antigenemia in HIV-infected patients.
Sun F, Xu XL, Lu YQ, Chen YK. Sun F, et al. Medicine (Baltimore). 2020 Oct 30;99(44):e22874. doi: 10.1097/MD.0000000000022874. Medicine (Baltimore). 2020. PMID: 33126335 Free PMC article.
44,514 results
You have reached the last available page of results. Please see the User Guide for more information.